Economic outcomes of antipsychotic agents in a medicaid population: Traditional agents vs. Risperidone

Psychopharmacology Bulletin

Volumn 34, Issue 3, 1998, Pages 373-382

  Nightengale, Brian S ^a   Crumly, John M ^b   Liao, Jason ^c   Lawrence, Bryan J ^d   Jacobs, Eigene W ^b  

^a XCENDA   (United States)

^b UNIVERSITY OF OKLAHOMA   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Antipsychotic medications; Pharmacoeconomics of schizophrenia therapies; Risperidone; Schizophrenia

Indexed keywords

BENZATROPINE; CHLORPROMAZINE; DIPHENHYDRAMINE; FLUPHENAZINE; HALOPERIDOL; PERPHENAZINE; RISPERIDONE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE; TRIHEXYPHENIDYL;

CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MEDICAL DECISION MAKING; MEDICAL RECORD; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; DATABASES, FACTUAL; FEMALE; HUMANS; MALE; MEDICAID; RISPERIDONE; UNITED STATES;

EID: 0031733792     PISSN: 00485764     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (27)

1. Addington, DE; Jones, B; Bloom, D; Chouinard, G; Remington, G; and Albright, P. Reduction of hospital days in chronic schizophrenic patients with risperidone: A retrospective study. Clin. Therapeut. 15:917-926, 1993.
2. Albright, P; Livingstone, S; and Deegan, D. Reduction of healthcare resource utilization and costs following the use of risperidone for patients with schizophrenia previously treated with standard antipsychotic therapy. Clin. Drug Invest. 11:289-299, 1996.
3. Chouinard, G; Jones, B; Remington, G; Addington, D; MacEwan, GW; Labelle, A; Beauclair, L; and Arnott, W. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J. Clin. Psychopharmacol. 13:25-40, 1993. [Erratum, 13:149, 1993.]
4. Claus, A; Bollen, J; De Cuyper, H; Eneman, M; Malfroid, M; Peuskens, J; and Heylen, S. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: A multicentre double-blind comparative study. Acta Psychiatr. Scand. 85:295-305, 1992.
5. Crane, GE. Clinical psychopharmacology in its 20th year: Late, unanticipated effects of neuroleptics may limit their use in psychiatry. Science 181:124-128, 1973.
6. Daniel, DG; Goldberg, TE; Weinberger, DR; Kleinman, JE; Pickar, D; Lubick, LJ; and Williams, TS. Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: A pilot study. Am. J. Psychiatry 153:417-419, 1996.
7. Ellenbroek, BA. Treatment of schizophrenia: A clinical and preclinical evaluation of neuroleptic drugs. Pharmacol. Ther. 57:1-78, 1993.
8. Ereshefsky, L. Challenges of antipsychotic medication in the elderly. Consult. Pharm. 10(Suppl. C):4-10, 1995.
9. Fichtner, CG; Hanrahan, P; and Luchins, DJ. Pharmacoeconomic studies of atypical antipsychotics: Review and perspective. Psychiatr. Ann. 28:381-396, 1998.
10. Finley, PR; Sommer, BR; Corbitt, JL; Brunson, GH; and Lum, BL. Risperidone: Clinical outcome predictors and cost-effectiveness in a naturalistic setting. Psychopharmacol. Bull. 34:75-81, 1998.
11. Heinrich, K; Kleiser, E; and Lehmann, E. Experimental comparison of the efficacy and compatibility of risperidone and clozapine in acute schizophrenia. In: Kane, JM, ed. Risperidone: Major Progress in Antipsychotic Treatment. Satellite Symposium at the 17th Congress of Collegium Internationale Neuropharmacologicum. Oxford, England: Oxford Clinical Communications, 1991.
12. Johnson, DAW. Drug treatment of schizophrenia. In: Bebbington, P, and McGuffin, P, eds. Schizophrenia: The Major Issues. Oxford, England: Heinemann Professional, 1988. pp. 158-171.
13. Kane, JM, and Marder, SR. Psychopharmacologic treatment of schizophrenia. Schizophr. Bull. 19:287-302, 1993.
14. Keith, SJ; Regier, DA; and Rae, DS. Schizophrenic disorders. In: Robins, LN, and Regier, DA, eds. Psychiatric Disorders in America: The Epidemiological Catchment Area Study. New York, Toronto: The Free Press, 1991.
15. Leysen, JE; Janssen, PFM; Schotte, A; Luyten, WH; and Megens, AA. Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: Role of 5HT2 receptors. Psychopharmacology 112:S40-S54, 1993.
16. Lieberman, AA, and Coburn, AF. The health of the chronically mentally ill: A review of the literature. Commun. Ment. Hlth. J. 22:104-116, 1986.
17. Lindstrom, E; Ericksson, B; Hellgren, A; von Knorring, L; and Eberhard, G. Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia. Clin. Therapeut. 17:402-412, 1995.
18. Littell, RC; Milliken, GA; and Stroup, WW. SAS System for Mixed Models. Cary, NC: SAS Institute, Inc., 1996. 633 pp.
19. Love, RC. Novel versus conventional antipsychotic drugs. Pharmacotherapy 16(1 Pt 2):6S-10S, 1996.
20. Marder, SR. Management of schizophrenia. J. Clin. Psychiatry 57(Suppl. 3):9-13, 1996.
21. Marder, SR, and Meibach, RC. Risperidone in the treatment of schizophrenia. Am. J. Psychiatry 151:825-835, 1984.
22. Nightengale, BS; Garrett, L; Waugh, SW; Lawrence, BJ; and Andrus, J. Economic outcomes associated with the use of risperidone in a naturalistic group practice setting. Am. J. Managed Care 4:360-366, 1998.
23. Sartorius, N, and de Girolamo, G. Preface to a special issue. Schizophr. Bull. 17:371-373, 1991.
24. SAS Institute, Inc. SAS/STAT User's Guide: Version 6.12. Cary, NC: SAS Institute, 1990.
25. Viale, G; Mechling, L; Maislin, G; Durkin, M; Engelhart, L; and Lawrence, B. Impact of risperidone on the use of mental health care resources. Psychiatr. Serv. 48:1153-1159, 1997.
26. World Health Organization. Manual of the International Statistical Classification of Diseases, Injuries and Causes of Death, 9th revision. Geneva: The Organization, 1977.
27. Wyatt, RJ. The cost of schizophrenia - Productive person years: Making direct and indirect costs understandable [Abstract]. Neuropsychopharmacology 10(3 Suppl.):597S, 1994.